Role of a Statistician in Drug Development in AI World

Oregon Convention Center 

Room: CC-F150 

Topic: Role of a Statistician in Drug Development in AI World

Abstract: AI and statisticians both handle significant amount of data. Can AI tools and statisticians offer the most desirable human-machine collaboration to advance solutions of complex problems that we have? Is there an ideal role of AI tools in conceptual design and optimization of clinical trials including identification of biomarkers? Are there risks of non-statisticians using AI tools and assume roles of pseudo statisticians to make wrong decisions? What are the most exciting advantages of AI as a tool to statisticians? Will there be best practices and guidance to use an AI tool in near future?

Panelists:

Brian Tracey
Director, Statistics,
Takeda, Boston, MA
brian.tracey@takeda.com

Paul Schuette
Scientific Computing Coordinator for the Office of Biostatistics – CDER, FDA
Silver Springs, Maryland
Paul.Schuette@fda.hhs.gov

Chris Miller
Vice President - Biometrics
Astra Zeneca
Gaithersburg - Maryland
chris.miller@astrazeneca.com

Kent Koprowicz
Vice President, DMC - Cytel
kent.koprowicz@cytel.com

Xiaochun Li, Professor
Department of Biostatistics and Health Data Science
Center for Computational Biology and Bioinformatics
School of Medicine, Fairbanks School of Public Health,
Indiana University, Indianapolis, IN
xiaochun@iu.edu

Yes

Section for Statistical Programmers and Analysts

Biopharmaceutical Section

Section on Statistical Computing